Paper41301080
Bridging Discovery and Treatment: Cancer Biomarker.
Liu H and 3 others. Cancers (Basel), 2025. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Bridging Discovery and Treatment: Cancer Biomarker. Papers, record 41301080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301080
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References149
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35058359 | Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/35058359 | PubMed |
| 2 | 37814010 | Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. | Nat Cancer | 2024 | https://conductscience.org/library/papers/37814010 | PubMed |
| 3 | 40827204 | Topology-aware pathway analysis of spatial transcriptomics. | PeerJ | 2025 | https://conductscience.org/library/papers/40827204 | PubMed |
| 4 | 34678434 | Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. | Cancer Lett | 2022 | https://conductscience.org/library/papers/34678434 | PubMed |
| 5 | 34571995 | D-2-Hydroxyglutarate in Glioma Biology. | Cells | 2021 | https://conductscience.org/library/papers/34571995 | PubMed |
| 6 | 25491647 | Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. | BMC Cancer | 2014 | https://conductscience.org/library/papers/25491647 | PubMed |
| 7 | 24875653 | Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. | J Natl Cancer Inst | 2014 | https://conductscience.org/library/papers/24875653 | PubMed |
| 8 | 21712485 | Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. | Oncologist | 2011 | https://conductscience.org/library/papers/21712485 | PubMed |
| 9 | 34392831 | ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. | Breast Cancer Res | 2021 | https://conductscience.org/library/papers/34392831 | PubMed |
| 10 | 22327623 | RET, ROS1 and ALK fusions in lung cancer. | Nat Med | 2012 | https://conductscience.org/library/papers/22327623 | PubMed |
| 11 | 32554709 | ctDNA monitoring using patient-specific sequencing and integration of variant reads. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32554709 | PubMed |
| 12 | 32306807 | Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. | Xenobiotica | 2020 | https://conductscience.org/library/papers/32306807 | PubMed |
| 13 | 28582845 | Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. | Cancer Biomark | 2017 | https://conductscience.org/library/papers/28582845 | PubMed |
| 14 | 32767659 | DNA in extracellular vesicles: biological and clinical aspects. | Mol Oncol | 2021 | https://conductscience.org/library/papers/32767659 | PubMed |
| 15 | 21889194 | BET bromodomain inhibition as a therapeutic strategy to target c-Myc. | Cell | 2011 | https://conductscience.org/library/papers/21889194 | PubMed |
| 16 | 34735635 | Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/34735635 | PubMed |
| 17 | 37124524 | Metabonomic analysis of tumor microenvironments: a mini-review. | Front Oncol | 2023 | https://conductscience.org/library/papers/37124524 | PubMed |
| 18 | 32111602 | Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32111602 | PubMed |
| 19 | 33842353 | Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. | Front Oncol | 2021 | https://conductscience.org/library/papers/33842353 | PubMed |
| 20 | 40299851 | Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer. | Cancer Discov | 2025 | https://conductscience.org/library/papers/40299851 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42866441 | Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation. | Gland Surg | 2026 | https://conductscience.org/library/papers/42866441 | PubMed |
| 42769460 | From Tumor Biology to Clinical Perspectives: Novel Biomarkers and Therapeutic Insights in Gastric Cancer. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769460 | PubMed |
| 42755971 | Functional outcomes and biochemical control after radical prostatectomy versus irreversible electroporation for localized prostate cancer. | iScience | 2026 | https://conductscience.org/library/papers/42755971 | PubMed |
| 42625235 | Targeting RASL12 by miR-6791-5p fuels malignant progression in lung adenocarcinoma. | Hereditas | 2026 | https://conductscience.org/library/papers/42625235 | PubMed |
| 42558819 | Stromal Laminin Subunit Alpha 3 is a Novel Prognostic Marker for Breast Cancer. | Clin Med Insights Oncol | 2026 | https://conductscience.org/library/papers/42558819 | PubMed |
| 42539880 | Targeting tumor transition windows. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42539880 | PubMed |
| 42510154 | The Association Between Neutrophil-to-Lymphocyte Ratio and Histological Tumor Differentiation in Solid Malignancies: A Systematic Review. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42510154 | PubMed |
| 42449743 | A Simulation-Based Stress-Testing Framework for Evaluating the Transportability of Imaging-Derived Logistic Risk Models Across Cutaneous Lesion Phenotypes. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42449743 | PubMed |
| 42423852 | The role of artificial intelligence in precision medicine for breast cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42423852 | PubMed |
| 42416401 | More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42416401 | PubMed |
| 42352240 | Translational Perspectives on Cell-Free Mitochondrial DNA as a Biomarker in Gynecological Cancers: Current Limitations and Future Research Directions. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352240 | PubMed |
| 42346225 | Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42346225 | PubMed |
| 42201477 | Bioinformatics analysis and preliminary clinical validation of ITGA9 and NPTX2 as prognosis-related genes in acute myeloid leukemia. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42201477 | PubMed |
| 42192906 | Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192906 | PubMed |
| 42164390 | Machine learning integration of multi-omics data develops a sarcomatoid-related renal cell carcinoma score (SARS) for prognosis stratification and guiding therapy. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42164390 | PubMed |
| 42122230 | Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122230 | PubMed |
| 42074564 | Non-Coding RNAs in Cancer: Decoding Regulatory Networks for Liquid Biopsy Applications. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42074564 | PubMed |
| 42029556 | High uPAR and Low miR-221 Expression Predict Poor Disease-Free Survival in Triple-Negative Breast Cancer. | Pathophysiology | 2026 | https://conductscience.org/library/papers/42029556 | PubMed |
| 41838687 | Multiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma. | PLoS One | 2026 | https://conductscience.org/library/papers/41838687 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41301080
GET https://conductscience.org/api/papers/v1/41301080/references?page=2